---
created: 2025-04-13
updated: 2025-04-13T10:52
id: qY?Crx]3jE
specialty: endo
specialty_id: 72
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::08-endocrinology::03-pancreas::04-treatment-of-diabetes
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy::sglt2-inhibitors
  - "source/ak-step1-v11:": 
  - theme/ome::14-endocrine::05-pancreas::03-diabetes-pharm
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::15-surgery:-general::07-pancreas
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::07-endocrine::07-sodium-glucose-cotransporter-2-(sglt2)-inhibitors
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::05-gi-&-endocrine::02-diabetes::02-metformin,-thiazolidinediones,-pramlintide,-sglt2-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::100-999::600-699::604
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::18000-18999::18959
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::endocrine::pharmacology"
type: flashcard
---

# Question
SGLT2 inhibitors (eg, canagliflozin, dapagliflozin) are contraindicated in patients with **renal insufficiency**

---

# Answer
Ineffective as renal function [eGFR] falls <30-45 mL/min/1.73 m2)  SGLT2 Sodium-glucose cotransporter-2 = reabsorbs 90% of filtered glucose *PT proximal tubule* SGLT-2 inhibitors == dec renal absorption of Na+ and glucose == antihyperglycemic effect  DM2 combination tx (eg, canagliflozin + metformin) = DM2 + PHx of MI, HF, nephropathy